NuCana (NASDAQ:NCNA) Cut to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of NuCana (NASDAQ:NCNA) from a buy rating to a hold rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “

A number of other research firms also recently weighed in on NCNA. William Blair reaffirmed an outperform rating on shares of NuCana in a research report on Thursday, May 16th. BidaskClub raised shares of NuCana from a strong sell rating to a sell rating in a research report on Wednesday, July 31st. Finally, ValuEngine raised shares of NuCana from a hold rating to a buy rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. NuCana currently has an average rating of Buy and an average price target of $23.50.



NuCana stock opened at $6.95 on Tuesday. The company has a market cap of $292.93 million, a P/E ratio of -12.19 and a beta of 3.27. NuCana has a 1-year low of $7.53 and a 1-year high of $30.10. The company has a fifty day simple moving average of $9.38 and a 200 day simple moving average of $12.59.

NuCana (NASDAQ:NCNA) last released its earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.22). As a group, analysts predict that NuCana will post -1.14 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Marshall Wace North America L.P. grew its position in shares of NuCana by 558.8% in the 1st quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock valued at $1,034,000 after acquiring an additional 51,607 shares during the period. Rothschild Investment Corp IL bought a new position in shares of NuCana in the 1st quarter valued at about $211,000. Asymmetry Capital Management L.P. grew its position in shares of NuCana by 5.4% in the 1st quarter. Asymmetry Capital Management L.P. now owns 45,393 shares of the company’s stock valued at $772,000 after acquiring an additional 2,346 shares during the period. Alps Advisors Inc. grew its position in shares of NuCana by 5.6% in the 1st quarter. Alps Advisors Inc. now owns 77,838 shares of the company’s stock valued at $1,323,000 after acquiring an additional 4,160 shares during the period. Finally, Susquehanna International Group LLP bought a new position in shares of NuCana in the 2nd quarter valued at about $139,000. 38.09% of the stock is owned by institutional investors.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.

Featured Article: Intrinsic Value and Stock Selection

Get a free copy of the Zacks research report on NuCana (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.